- Home
- SBI vs LPTX Comparison
SBI vs LPTX Comparison
Compare SBI & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBI
- LPTX
- Stock Information
- Founded
- SBI 1992
- LPTX 2011
- Country
- SBI United States
- LPTX United States
- Employees
- SBI N/A
- LPTX N/A
- Industry
- SBI Finance/Investors Services
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SBI Finance
- LPTX Health Care
- Exchange
- SBI Nasdaq
- LPTX Nasdaq
- Market Cap
- SBI 110.5M
- LPTX 119.6M
- IPO Year
- SBI N/A
- LPTX N/A
- Fundamental
- Price
- SBI $7.88
- LPTX $2.46
- Analyst Decision
- SBI
- LPTX Strong Buy
- Analyst Count
- SBI 0
- LPTX 3
- Target Price
- SBI N/A
- LPTX $7.50
- AVG Volume (30 Days)
- SBI 39.5K
- LPTX 335.2K
- Earning Date
- SBI 01-01-0001
- LPTX 11-13-2024
- Dividend Yield
- SBI 4.52%
- LPTX N/A
- EPS Growth
- SBI N/A
- LPTX N/A
- EPS
- SBI N/A
- LPTX N/A
- Revenue
- SBI N/A
- LPTX N/A
- Revenue This Year
- SBI N/A
- LPTX N/A
- Revenue Next Year
- SBI N/A
- LPTX N/A
- P/E Ratio
- SBI N/A
- LPTX N/A
- Revenue Growth
- SBI N/A
- LPTX N/A
- 52 Week Low
- SBI $6.96
- LPTX $1.68
- 52 Week High
- SBI $8.00
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- SBI 52.92
- LPTX 35.65
- Support Level
- SBI $7.64
- LPTX $2.88
- Resistance Level
- SBI $7.87
- LPTX $3.27
- Average True Range (ATR)
- SBI 0.07
- LPTX 0.30
- MACD
- SBI 0.02
- LPTX -0.08
- Stochastic Oscillator
- SBI 82.76
- LPTX 12.50
About SBI Western Asset Intermediate Muni Fund Inc
Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .